Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome

Anger, Jennifer T.; Zabihi, Nasim; Clemens, J. Quentin; Payne, Christopher K.; Saigal, Christopher S.; Rodríguez, Larissa V.

doi:10.1007/s00192-010-1252-8

Cited by 45 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesize that PPS treatment likely led to a significant reduction in pain of the MPS animals, contributing to the increased motility. A reduction in pain also is the most prominent change in IC patients treated with PPS [10], [21]. There also were clear changes in the articular chondrocytes that suggested improved articular joint function, which together with improvements in bone morphology and spine biomechanics might be partly responsible as well.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Pentosan Polysulfate: A Novel Therapy for the Mucopolysaccharidoses

Schuchman

Lai

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundPentosan polysulfate (PPS) is an FDA-approved, oral medication with anti-inflammatory and pro-chondrogenic properties. We have previously shown that animal models of the mucopolysaccharidoses (MPS) exhibit significant inflammatory disease, contributing to cartilage degeneration. Enzyme replacement therapy (ERT) only partly reduced inflammation, and anti-TNF-alpha antibody therapy significantly enhanced clinical and pathological outcomes. Here we describe the use of PPS for the treatment of MPS type VI rats.Methodology/Principal FindingsTreatment began during prenatal development and at 1 and 6 months of age. All animals were treated until they were 9 months old. Significant reductions in the serum and tissue levels of several inflammatory markers (e.g., TNF-alpha, MIP-1alpha and RANTES/CCL5) were observed, as was reduced expression of inflammatory markers in cultured articular chondrocytes. ADAMTS-5/aggrecanase-2 levels also were reduced in chondrocytes, consistent with an elevation of serum tissue inhibitor of metalloproteinase 1. Marked improvements in motility and grooming behavior occurred, along with a reduction in eye and nasal secretions and a lessening of the tracheal deformities. MicroCT and radiographic analyses further revealed that the treated MPS skulls were longer and thinner, and that the teeth malocclusions, misalignments and mineral densities were improved. MicroCT analysis of the femurs and vertebrae revealed improvements in trabecular bone mineral densities, number and spacing in a subset of treated MPS animals. Biomechanical assessments of PPS-treated spines showed partially restored torsional behaviors, suggesting increased spinal stability. No improvements were observed in cortical bone or femur length. The positive changes in the PPS-treated MPS VI rats occurred despite glycosaminoglycan accumulation in their tissues.ConclusionsBased on these findings we conclude that PPS could be a simple and effective therapy for MPS that might provide significant clinical benefits alone and in combination with other therapies.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Pentosan polysulfate (PPS) is an FDA-approved, oral medication (Elmiron®) with potent anti-inflammatory effects that is used to treat patients with interstitial cystitis (IC) [10]. It also has been shown to promote chondrogenesis in animals with osteoarthritis (OA) [11]–[13], and has been used off-label to treat OA patients [14]–[15].…”

Section: Introductionmentioning

confidence: 99%

Pentosan Polysulfate: A Novel Therapy for the Mucopolysaccharidoses

Schuchman

Lai

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Berry and co-authors report the prevalence of IC/BPS at between 3 and 8 million women in the United States [3]. Few patients achieve long-term remission of symptoms despite a range of treatments [1,33]. A substantial body of research has explored bladder pathology and other peripheral tissue abnormalities, however, a large number of IC/BPS patients lack any discernible end organ inflammation, and do not respond to treatment of peripheral tissues (e.g.…”

Section: Introductionmentioning

confidence: 99%

Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms

Schrepf

O’Donnell

Luo

et al. 2014

Pain

View full text Add to dashboard Cite

“…149 A 2011 study found the U.S. direct costs of IC to be $22 billion. 150 Chronic Headache (Migraine and Tension-Type) Both migraine and tensiontype headaches are defined as primary headache disorders, i.e., those that exist independent of another disorder. These headache disorders are classified as chronic when they occur 15 days or more a month for three months in the absence of medication use (migraine) 161 or for six months (chronic tension-type).…”

Section: Irritable Bowel Syndrome (Ibs)mentioning

confidence: 99%

The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome: An Observational Study Using Routine Health Insurance Data

Haüser

Marschall

Layer

et al. 2019

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

The Chronic Pain Research Alliance (CPRA) exists to provide a voice for the millions of people suffering with multiple pain conditions, termed Chronic Overlapping Pain Conditions (COPCs). These conditions come at a high cost -to the individuals affected by them, their loved ones and to our health care system and society at large. Misdiagnosis is all too common, coordinated medical care is lacking, and safe and effective treatments are sparse.Why is this? A major reason is that only $1.06 per affected person is invested in researching these conditions by the federal government.We are working tirelessly to change that! For meaningful change to occur in the lives of those suffering from COPCs, CPRA understands that all invested stakeholders must work together. This includes patients affected by COPCs and their loved ones, clinicians who care for them, scientists researching these conditions, companies working to develop better and more effective treatments, federal and private research agencies who support research studies, advocacy organizations working to improve the lives of people with these conditions and legislators who affect change through public policy.With the ultimate goal of advancing timely diagnoses and effective evidence-based medical management for individuals affected by COPCs, the CPRA works with invested stakeholders to:1 -Promote high-quality research on chronic overlapping pain conditions 2 -Translate research findings into information for patients and educational training programs for clinicians 3 -Drive the development of safe and effective treatments for these conditions CPRA's Vision for the Future With the advancement of initiatives called for by the CPRA, we envision a future where individuals with COPCs will receive a timely and accurate diagnosis, following by high-quality, comprehensive medical care that is informed by the latest and most rigorous scientific evidence.In the process, these goals will be attained: Increased federal and private investment in COPCs research that is coordinated, standardized and collaborative  Informed and educated health care professionals  Informed and empowered patients  Development of safe and effective therapies specific to COPCs  Maximized taxpayer dollars and decreased costsTo learn more, please visit: www.ChronicPainResearch.org.

show abstract

Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome

Cited by 45 publications

References 22 publications

Pentosan Polysulfate: A Novel Therapy for the Mucopolysaccharidoses

Pentosan Polysulfate: A Novel Therapy for the Mucopolysaccharidoses

Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms

The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome: An Observational Study Using Routine Health Insurance Data

Contact Info

Product

Resources

About